SCHEDULE 13G/A: Acorn Bioventures Entities and Anders Hove Disclose Significant Passive Stake in Puma Biotechnology, Inc.

Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., their general partners, and manager Anders Hove have filed an amended Schedule 13G, disclosing their collective passive beneficial ownership of 8.0% of Puma Biotechnology, Inc.'s common stock as of December 31, 2024.

Summary

• Acorn Bioventures, L.P. beneficially owns 1,654,823 shares of Puma Biotechnology, Inc. common stock, representing 3.3% of the class.
• Acorn Bioventures 2, L.P. beneficially owns 2,285,229 shares of Puma Biotechnology, Inc. common stock, representing 4.7% of the class.
• Acorn Capital Advisors GP, LLC, as the general partner of Acorn Bioventures, L.P., is deemed to beneficially own 1,654,823 shares, or 3.3% of the class.
• Acorn Capital Advisors GP 2, LLC, as the general partner of Acorn Bioventures 2, L.P., is deemed to beneficially own 2,285,229 shares, or 4.7% of the class.
• Anders Hove, as the manager of both Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, is deemed to beneficially own an aggregate of 3,940,052 shares, representing 8.0% of the class.
• The percentages are calculated based on 49,067,348 shares of Common Stock outstanding as of December 31, 2024, as reported by Bloomberg.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Puma Biotechnology, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no positive or negative operational or financial news about the issuer. Its sentiment is neutral.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of passive beneficial ownership by investment entities in a publicly traded biotechnology company. It does not provide specific insights into Puma Biotechnology, Inc.'s operational performance or strategic direction, but rather reflects an investment position by a group of related entities.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors, which can be relevant for understanding the shareholder base.

Key Dates

Keywords

Puma Biotechnology, Acorn Bioventures, Anders Hove, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Biotechnology Investment, Institutional Ownership